Table 2 Distribution of different miR-6076 and CYP2C19 genotypes and clinical characteristics among patients experiencing bleeding during clopidogrel treatment
Variable | Bleeding | Non-bleeding | P | |
|---|---|---|---|---|
No. (%) | No. (%) | |||
CYP2C19*2 | GG | 18 (6.5) | 257 (93.5) | 0.901 |
rs4244285 | GA | 16 (6.8) | 218 (93.2) | |
AA | 2 (4.3) | 45 (95.7) | ||
CYP2C19*3 | GG | 33 (6.3) | 489 (93.7) | 0.368 |
rs4986893 | GA | 4 (10.0) | 36 (90.0) | |
AA | 0 | 1 (100.0) | ||
miR-6076 | TT | 12 (3.1) | 373 (96.9) | < 0.001 |
rs1463411 | GT | 22 (13.2) | 145 (86.8) | |
GG | 3 (27.3) | 8 (72.7) | ||
ACEI/ARB | 11 (3.1) | 343 (96.9) | < 0.001 | |